The sold production of composite diagnostic or laboratory reagents in Poland has seen significant growth over the past decade. Starting from a value of 9.7386 million euros in 2013, it witnessed a notable increase and achieved 39.222 million euros by 2023. Year-on-year variations indicate periods of both rapid growth, such as in 2016 (64.48%) and 2019 (38.24%), and slight declines as in 2018 (-2%) and 2020 (-3.12%). The compound annual growth rate (CAGR) over the last five years has been healthy at 8.88%, reflecting a steady growth trajectory.
Looking ahead, the forecasted data suggests continued positive growth, with a 5-year CAGR of 3.03% and an overall growth rate of 16.11% by 2028. The value of sold production is anticipated to exceed 47.579 million euros by 2028.
Future trends to watch for include technological advancements in diagnostics and laboratory reagents, increased investment in healthcare infrastructure, and potential regulatory changes within the EU that could impact production and sales. Additionally, the growing importance of personalized medicine and the rise of preventive healthcare are likely to drive demand further.
